Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.
Lisa Astor
Advertisement
Articles by Lisa Astor
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Melanoma Vaccine Receives FDA Fast Track Designation
2
TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML
3
Duvelisib Shows Significant Activity in R/R Peripheral T-Cell Lymphoma
4
In Vivo CAR Engineering and the Next Phase of Cellular Immunotherapy
5